OCU400 Round 3 Enrollment Completed: Ocugen has completed enrollment in the liMeliGhT trial (140 patients) and expects peak data in Q1 2027, targeting a rolling BLA start in Q3 2026 to support potential approval in 2027.
Stargard and GA programs are progressing: GARDian3 is ahead of schedule with Phase II/III topline data expected in Q2 2027 and EMA has confirmed that a US trial could support the European filing, while Phase II ArMaDa GA data showed a 46% reduction in lesion growth at 12 months and Phase III is planned for 2026.
High consumption but funded in late 2026: R&D increased to $39.8M in 2025 and net loss per share increased to $0.23 with cash flow in Q4 2026 (may extend to Q2 2027 if $30M warrant is exercised).
At Ocugen, Inc. Interested in? Here are five stocks we like best.
Ocugen (NASDAQ: OCGN ) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight late-stage progress in its regenerative gene therapy pipeline, outline future regulatory milestones, and review higher operating expenses during the extended cash 2024 fiscal year.
Chairman, CEO, and co-founder Dr. Shankar Masnoori said 2025 was “a transformative year,” citing progress made across the company’s programs, regional partnership activity, and leadership appointments as Ocugen works toward a commercial-stage company.
→ Defense stocks are on the rise — aerospace earnings could close the gap
Enrollment is now complete in the Phase III liMeliGhT trial of OCU400 in retinitis pigmentosa (RP), Massonuri said. He described liMeliGhT as widespread RP, a gene-agnostic phase III orphan gene therapy study, and said that nearly 300,000 people in the United States and Europe are living with RP caused by mutations in more than 100 genes.
According to management, OCU400 is designed as a modifier gene therapy using NR2E3 to address multiple mutations with a single treatment. Musunuri contrasts the only approved gene therapy for RP, which targets RPE65 and accounts for approximately 1% to 2% of RP patients, and said Ocugen believes OCU400 can cure 98% to 99% of RP patients.
→ IonQ in rebound mode: buy the article, respect the risk
The company said liMeliGhT enrolled 140 patients in a randomized 2:1 RHO and gene-agnostic arm into treatment and no-treatment control groups. The primary endpoint is the 12-month change in visual function assessed by the Luminance Dependent Navigation Assessment (LDNA), measured by the improvement in locus of control from baseline to 12 months. Management said top-line data is expected in the first quarter of 2027, which it expects to support the filing of a Biologics License Application (BLA) and possible approval in 2027.
Okogen also discussed positive long-term three-year Phase I/II data for OCU400, which management said showed a sustained, clinically meaningful gain of nearly two lines in low-light visual acuity (LLVA), with no new treatment-related serious adverse events or adverse events of interest.
→ Supermicro: Why NVIDIA Shadow is a useful niche
Masunori said Okogen remains on track to begin BLA submissions in the third quarter of 2026, while process validation and production activities are progressing in support of that timeline. He added that planning and marketing initiatives are being scaled up as the company hopes to commercialize in 2027.
In a Q&A, Dr. Huma Qamar said the company is “very confident” of meeting the timeline for turning over the liMeliGhT data after the 12-month initial deadline. She explained that LDNA is based on the mobility test that was the primary endpoint for Luxturna (called MLMT at the time), and said that Okogen’s version uses a uniform lux level from 0 to 9 and is designed to capture change from baseline through 52 weeks. Qamar also said that a clinically meaningful improvement would be “greater than or equal to 1 lux level.”
Okogen said its OCU410ST program for Stargardt disease targets more than 1,200 pathogenic ABCA4 mutations with a single treatment. Missonuri said Stargardt affects nearly 100,000 patients in the United States and Europe, with no approved treatment.
Management said the Phase II/III main confirmatory trial of GARDian3 remains ahead of schedule, with top-line Phase II/III data expected in the second quarter of 2027 following BLA submission. Missonuri also noted the peer-reviewed publication of the Guardian’s Phase 1 results in the journal eyeswhich he said supports the treatment’s safety, tolerability and efficacy profile.
One key regulatory update from the call: Missonuri said the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) confirmed that data from Ocugen’s US-based trial could support the EMA application. He said the alignment allows Okogen to maintain the same schedule and budget efficiency as in Europe.
Okogen also discussed ellipsoid zone (EZ) analysis as an exploratory endpoint in his Stargardt and geographic atrophy (GA) tests. Management described EZ as a biomarker of photoreceptor structural integrity and metabolic health, and stated that EZ changes may occur before the progression of visual retinal pigment epithelium atrophy. Massonori said the move is related to the company’s focus on showing profitability within a year.
During the Q&A, Masnoori and Qamar discussed the competitive dynamics at Stargard. Massonori said Okogen is pursuing a “one-and-done” treatment that aims to address major pathways and “reset homeostasis,” adding that the company is not concerned if other treatments reach the market first. Qamar added that Okogen’s trial included patients three years of age and older and was designed to represent early to advanced disease.
For OCU410 in secondary to late-stage GA for dry age-related macular degeneration, Massonuri identified a significant population of approximately 2 million to 3 million patients in the United States and Europe combined. He said OCU410 is designed to target multiple disease pathways, while currently approved drugs target the complement system and require frequent intrauterine injections. Massonuri also said that GA treatments have not been approved in Europe and that existing FDA-approved options have not shown meaningful functional results.
In January, Okogen announced preliminary 12-month data from 50% of patients evaluated so far in the Phase II ArMaDa trial. Massonuri said the company saw a 46% reduction in lesion growth in the medium and high-dose groups versus controls at 12 months, with statistical significance (P = 0.015) in a group of 23 patients, and a 50% responder rate based on lesion size control greater than 50%. He also addressed the subgroup analysis of patients with a baseline GA measurement of 7.5 mm2 or more showed a 57% reduction in lesion growth for the medium dose and a 56% reduction for the high dose compared to the control.
Management said the data set also included Phase I findings in which OCU410-treated eyes showed 60% slower EZ loss than untreated fellow eyes. Missonuri said Okogen expects to report the complete dataset from Phase II this month and expects to begin Phase III in 2026.
In the Q&A, Massonori said that dose selection and inclusion criteria for phase III will be evaluated after a complete dataset is available, noting that gene therapy may require a threshold and may not show a conventional dose response after reaching that threshold. Management also said it will evaluate whether to limit baseline lesion sizes based on Phase II studies in Phase III.
Okogen said OCU200 has so far had no product-related serious adverse events or product-related adverse events in its Phase 1 food product, and enrollment is expected to be completed in the first quarter of 2026. For the OCU500, the company said the National Institute of Allergy and Infectious Diseases (NIAID) intends for a second trimester test. The year 2026.
Massonuri also said that Ocogen has created Ocucelix as a wholly-owned subsidiary for new reproductive cell therapy assets, including the new CART, which aims to be independently financed to “maximize value for Ocogen’s shareholders and patients.”
In the partnership, Masunori said Okogen has executed its first regional licensing agreement for the exclusive Korean rights to OCU400 in 2025 with Kwangdong Pharmaceutical Co., Ltd. He said the deal includes upfront fees, near-term development milestones, and royalties, and is part of a strategy to pursue regional partnerships while retaining commercial rights in the US and Europe.
Chief Financial Officer Rita Johnson-Green reported higher research and development spending during the year. R&D expense for the fourth quarter was $10.7 million, compared to $8.3 million in the prior year quarter. General and administrative expenses were $6.1 million compared to $6.3 million in the prior-year quarter. Okogen reported a net loss of $0.06 per common share for the quarter, compared to a net loss of $0.05 per share in the year-ago quarter.
For the full year 2025, Ocugen reported:
R&D Cost: $39.8 million (vs. $32.1 million in 2024)
G&A Expense: $27.6 million (vs. $26.7 million in 2024)
Net loss per share: $0.23 (vs. $0.20 in 2024)
Johnson-Greene said cash and cash equivalents extend the run through the fourth quarter of 2026, including a recently filed $22.5 million direct offering for common stock led by RTW Investments. She added that if the $30 million in guarantees from Janus Henderson’s prior raise is fully exercised, the cash flow would extend into the second quarter of 2027.
Looking ahead, Masunori cited several 2026 catalysts, including full Phase II data for OCU410 “this month,” enrollment of OCU410ST in early 2026, the start of Phase III for OCU410 in 2026, and the start of BLA submissions for OCU204020433.
Ocugen Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address the needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to develop new therapies aimed at protecting and restoring vision, while leveraging strategic partnerships to expand its vaccine pipeline.
Within its gene therapy portfolio, Okogen is developing several programs targeting retinal disorders.
The article “Ocugen Q4 Earnings Highlights” was originally published by MarketBeat.
